Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide Neoadjuvant Therapy in High-Risk Prostate Cancer
NCT04997252Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Feb 2021
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Radiographic Progression-Free Survival at 24 months. Started Feb 2021; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04997252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997252.